Insilico and CMS launch drug discovery collaborations for CNS diseases
Published: 08 Apr 2026
Author: Towards Healthcare
Insilico Medicine announced collaborations with China Medical System (CMS) across several projects in the central nervous system (CNS) and autoimmune diseases. The companies jointly develop two R&D programmes using Insilico Medicine’s AI platform with CMS expertise in clinical development.
The collaboration framework is designed to integrate resources across the entire drug development value chain, from target identification and small-molecule design through preclinical validation, clinical strategy, regulatory planning, and commercialisation. Insilico will contribute its AI-enabled capabilities to efficiently screen and optimise candidate molecules, while CMS will leverage its clinical development networks and regulatory expertise to advance projects from preclinical stages into clinical trials.
The market is driven by AI-driven drug discovery.
According to Towards Healthcare, the Small Molecule Drug Discovery Outsourcing Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 9.67 billion in 2026 to approximately USD 20.5 billion by 2035, representing a compound annual growth rate (CAGR) of 8.7% from 2026 to 2035. Growth is driven by increasing investment in drug discovery and development, with innovative solutions and advanced technology enhancing the efficiency and effectiveness of the drug discovery process.
AI empowered drug discovery
Collaboration with the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep disease-area expertise to jointly advance the co-development of no fewer than two R&D programs.
Insilico Medicine expects to receive R&D funding support of up to several tens of millions of HKD for each program. This collaboration will fully leverage the complementary strengths of both parties across the entire value chain of drug discovery, clinical development, and commercialisation.
Co-CEO, chief scientific officer of Insilico Medicine, Feng Ren said: “This strategic collaboration with CMS is a key step for Insilico Medicine in advancing our mission of ‘AI empowered, full lifecycle innovative drug R&D”
A recent report by Towards Packaging highlights that the Small Molecule Drug Discovery Outsourcing Market is witnessing growing approval of small molecule drugs with advancements in medical technology, rising demand for cost-effective innovation, and a shift towards a virtual pharmaceutical model.